Filippo De Marinis

Summary

Country: Italy

Publications

  1. ncbi Pemetrexed in second-line treatment of non-small-cell lung cancer
    Filippo De Marinis
    Pulmonary Oncology Unit, Department of Lung Diseases, Forlanini Hospital, Rome, Italy
    Oncology (Williston Park) 18:38-42. 2004
  2. ncbi A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer
    M Rita Migliorino
    5th Pneumoncology Unit, Department of Lung Diseases, San Camillo-Forlanini Hospital, V. Portuense 332, 00149 Rome, Italy
    Lung Cancer 35:319-27. 2002
  3. ncbi Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma
    Marcello Tiseo
    Division of Medical Oncology, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Tumori 93:138-44. 2007
  4. ncbi Role of induction chemotherapy in resectable N2 non-small cell lung cancer
    Filippo De Marinis
    Department of Lung Diseases, San Camillo-Forlanini Hospitals, Rome, Italy
    J Thorac Oncol 2:S31-4. 2007
  5. ncbi Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies
    Filippo De Marinis
    5th Pneumo Oncology Unit, Department of Oncology, S Camillo Forlanini Hospitals, Rome, Italy
    Semin Oncol 33:S17-24. 2006
  6. ncbi Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel
    Filippo De Marinis
    Thoracic Oncology Unit I, Chief Carlo Forlanini Hospital, Rome, Italy
    J Thorac Oncol 4:1280-8. 2009
  7. ncbi Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer
    Filippo De Marinis
    Thoracic Oncology Unit I, Chief Carlo Forlanini Hospital, Pza Forlanini 1, 00151, Rome, Italy
    Oncologist 13:14-20. 2008
  8. ncbi Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer
    Filippo De Marinis
    Forlanini Hospital, Rome, Italy
    J Thorac Oncol 3:30-6. 2008
  9. ncbi Second-line chemotherapy for non-small cell lung cancer
    F De Marinis
    5th Pneumo Oncology Unit, Department of Oncology, San Camillo Forlanini Hospitals, Rome, Italy
    Ann Oncol 17:v68-71. 2006
  10. ncbi Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma: a Phase II multicenter study
    Filippo De Marinis
    Fifth Operative Unit of Pulmonary Oncology, Carlo Forlanini Hospital, Rome, Italy
    Cancer 98:1707-15. 2003

Detail Information

Publications46

  1. ncbi Pemetrexed in second-line treatment of non-small-cell lung cancer
    Filippo De Marinis
    Pulmonary Oncology Unit, Department of Lung Diseases, Forlanini Hospital, Rome, Italy
    Oncology (Williston Park) 18:38-42. 2004
    ..These results support the use of pemetrexed as a new option in the second-line treatment of NSCLC...
  2. ncbi A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer
    M Rita Migliorino
    5th Pneumoncology Unit, Department of Lung Diseases, San Camillo-Forlanini Hospital, V. Portuense 332, 00149 Rome, Italy
    Lung Cancer 35:319-27. 2002
    ..This suggests a need for a multimodality approach upfront, such as concurrent chemoradiation therapy, particularly in patients with Stage IIIB disease...
  3. ncbi Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma
    Marcello Tiseo
    Division of Medical Oncology, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Tumori 93:138-44. 2007
    ..In our Institutions, cisplatin chemotherapy is an outpatient treatment that provides adequate hydration with an NaCl solution plus furosemide and diuresis monitoring during treatment...
  4. ncbi Role of induction chemotherapy in resectable N2 non-small cell lung cancer
    Filippo De Marinis
    Department of Lung Diseases, San Camillo-Forlanini Hospitals, Rome, Italy
    J Thorac Oncol 2:S31-4. 2007
  5. ncbi Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies
    Filippo De Marinis
    5th Pneumo Oncology Unit, Department of Oncology, S Camillo Forlanini Hospitals, Rome, Italy
    Semin Oncol 33:S17-24. 2006
    ....
  6. ncbi Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel
    Filippo De Marinis
    Thoracic Oncology Unit I, Chief Carlo Forlanini Hospital, Rome, Italy
    J Thorac Oncol 4:1280-8. 2009
    ....
  7. ncbi Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer
    Filippo De Marinis
    Thoracic Oncology Unit I, Chief Carlo Forlanini Hospital, Pza Forlanini 1, 00151, Rome, Italy
    Oncologist 13:14-20. 2008
    ..This review focuses on these drugs, dealing with the results supporting the choice among docetaxel, pemetrexed, and erlotinib in second- and/or third-line treatment...
  8. ncbi Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer
    Filippo De Marinis
    Forlanini Hospital, Rome, Italy
    J Thorac Oncol 3:30-6. 2008
    ..The low response rates and minimal survival gains observed in second-line studies underscore the need to assess treatment efficacy with symptomatic end points...
  9. ncbi Second-line chemotherapy for non-small cell lung cancer
    F De Marinis
    5th Pneumo Oncology Unit, Department of Oncology, San Camillo Forlanini Hospitals, Rome, Italy
    Ann Oncol 17:v68-71. 2006
    ..Finally, we will give a brief overview on current trials, that mainly explore the possibility to raise pemetrexed dose, and thus to increase its activity while maintaining an acceptable toxicity...
  10. ncbi Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma: a Phase II multicenter study
    Filippo De Marinis
    Fifth Operative Unit of Pulmonary Oncology, Carlo Forlanini Hospital, Rome, Italy
    Cancer 98:1707-15. 2003
    ....
  11. ncbi Docetaxel administered every two weeks as second-line chemotherapy for advanced non-small cell lung cancer: a phase II study
    Luigi De Petris
    5th Pneumo-Oncology Unit, Department of Oncology, S. Camillo-Forlanini Hospitals, V. Portuense 332, 00149 Rome, Italy
    Anticancer Res 25:4713-7. 2005
    ..Though non-hematological toxicity is significantly reduced, myelosuppression is still a matter of concern...
  12. ncbi A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma
    Filippo De Marinis
    Fifth Operative Unit of Pulmonary Oncology, Carlo Forlanini Hospital, Rome, Italy
    Cancer 103:772-9. 2005
    ....
  13. ncbi Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin
    Anna Ceribelli
    Department of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy
    Cancer 98:337-43. 2003
    ....
  14. ncbi Induction therapy with paclitaxel and carboplatin followed by hyperfractionated radiotherapy plus weekly concurrent chemotherapy and subsequent consolidation therapy in unresectable locally advanced non-small-cell lung cancer
    Enrico Cortesi
    Medical Oncology B, Policlinico Umberto I Hospital, La Sapienza University, Rome, Italy
    Tumori 93:133-7. 2007
    ....
  15. ncbi Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines
    Filippo De Marinis
    Pulmonary Oncology Unit, San Camillo Forlanini Hospitals, Rome, Italy
    Lung Cancer 73:1-10. 2011
    ..Guidelines were developed by answering clinical relevant questions. Here we report only major clinical issues concerning the management of advanced non-small-cell lung cancer (NSCLC)...
  16. ncbi A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer
    Ottavio Ariganello
    Department of Lung Diseases, 5th Pulmonary-Oncological Unit, S. Camillo-Forlanini Hospitals, Via Portuense 332, 00149 Rome, Italy
    Lung Cancer 46:119-24. 2004
    ..9 g/dL even in advanced lung cancer patients with a moderate/severe anemia, without RBC transfusion requirements. A randomized study of the proposed induction dose of epoetin alfa 40.000 IU is actually ongoing...
  17. ncbi Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma
    Luigi Portalone
    16th Pneumo Oncology Unit, C Forlanini Hospital, Rome, Italy
    Tumori 91:15-8. 2005
    ..The role of interleukin-2 in maintenance therapy for malignant pleural mesothelioma is encouraging and requires further study...
  18. ncbi EGFR inhibitors: clinical results
    Filippo De Marinis
    Fifth Operative Unit of Pulmonary Oncology, Department of Respiratory Diseases, Carlo Forlanini Hospital, Rome, Italy
    Suppl Tumori 1:S5-6. 2002
  19. ncbi Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer
    Filippo De Marinis
    Department of Lung Diseases, 5th Pulmonary Oncology Unit, Azienda Ospedaliera San Camillo Forlanini, Via Portuense 332, 00149, Rome, Italy
    Lung Cancer 39:331-8. 2003
    ..0 and 10 months, respectively, with a 1-year survival probability of 37.5%. CONCLUSIONS: The combination of PEG is feasible and well tolerated as front-line chemotherapy in SCLC. A randomized comparison of this triplet is underway...
  20. ncbi Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?
    Antonio Passaro
    Division of Medical Oncology, Sapienza University of Rome, Viale Regina Elena, 324 00161, Rome, Italy
    Expert Rev Anticancer Ther 11:1587-97. 2011
    ..Considering the different predictive and prognostic factors, tyrosine kinase inhibitors could be a valid option for second-line treatment of NSCLC...
  21. ncbi Treatment of bone metastases in lung cancer: the actual role of zoledronic acid
    Serena Ricciardi
    Thoracic Oncology Unit 1st, Lung Diseases Department, San Camillo Forlanin High Specialization Hospitals, Rome, Italy
    Rev Recent Clin Trials 4:205-11. 2009
    ..Zoledronic acid is the first and only bisphosphonate that has proven efficacy for the treatment of bone metastases from a broad range of solid tumor types, including lung cancer...
  22. ncbi New agents in advanced non-small-cell lung cancer treatment
    Serena Ricciardi
    Thoracic Oncology Unit 1st, Lung Diseases Department, San Camillo Forlanini High Specialization Hospitals, Rome, Italy
    Oncology 77:103-12. 2009
    ..Further investigations into adverse events with targeted therapy are urgently needed as these impact an increasing number of patients...
  23. ncbi Multimodality management of non-small cell lung cancer patients with brain metastases
    Serena Ricciardi
    Thoracic Oncology Unit 1st, Lung Diseases Department, San Camillo Forlanini High Specialization Hospitals, Rome, Italy
    Curr Opin Oncol 22:86-93. 2010
    ..Commonly, brain metastases are discovered after the diagnosis of cancer, often after other systemic metastases have developed. In this review article, we present the standard treatment approach and discuss new directions...
  24. ncbi Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer
    Bruno Gori
    High Specialization Hospitals, Oncological Pulmonary 1st Unit, San Camillo Forlanini, Rome, Italy
    Expert Opin Ther Targets 16:S55-60. 2012
    ..It plays a central role in the right choice of treatment, in an aim to give the best drug to the right patients, overcoming other well known prognostic factors...
  25. ncbi Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC)
    Evelina Miele
    Department of Experimental Medicine University of Rome Sapienza viale Regina Elena 324, Rome, Italy
    J Exp Clin Cancer Res 27:52. 2008
    ..This review focuses on radiotracers used for PET scan with particular attention to Non Small Cell Lung Cancer diagnosis, staging, response to treatment and follow-up...
  26. ncbi Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
    Serena Ricciardi
    Thoracic Oncology Unit 1st, Lung Diseases Department, San Camillo Forlanini High Specialization Hospitals, Rome, Italy
    Ther Clin Risk Manag 5:781-7. 2009
    ..The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study...
  27. ncbi New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond
    Bruno Gori
    Oncological Pulmonary Unit 1st, San Camillo Hospital, Rome, Italy
    Ther Clin Risk Manag 7:429-40. 2011
    ....
  28. ncbi Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer
    Francesco Grossi
    Medical Oncology A, Disease Management Team, Lung Cancer, National Institute for Cancer Research, Largo Rosanna Benzi 10, 16132 Genoa, Italy
    Crit Rev Oncol Hematol 67:16-26. 2008
    ....
  29. ncbi Second-line treatment of advanced non-small cell lung cancer
    Cesare Gridelli
    Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 3:430-40. 2008
    ..Further research is mandatory, to find better treatments, and to identify clinical and molecular predictive markers of efficacy, both for chemotherapy and for novel biologic agents...
  30. ncbi Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    Giorgio Vittorio Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Hospital, Regione Gonzole, 10, Orbassano Torino, Italy
    J Clin Oncol 26:3543-51. 2008
    ..Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting...
  31. ncbi Phase II study of Taxol combined With ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer
    Alberto Zaniboni
    UO di Oncologia Medica, Casa di Cura Poliambulanza, Brescia, Italy
    Am J Clin Oncol 26:84-8. 2003
    ..Randomized studies both versus carboplatin-paclitaxel and other triplets are clearly warranted...
  32. ncbi Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy
    Enrico Cortesi
    Medical Oncology, La Sapienza University, Viale del Policlinico, 00161 Rome, Italy
    Oncologist 9:459-68. 2004
    ..Objective. This open-label, nonrandomized, historically controlled study was conducted to evaluate the efficacy and safety of an induction dose of epoetin alfa in patients with moderate or severe anemia who were receiving chemotherapy...
  33. ncbi [The dilemma of first-line chemotherapy in advanced non-small-cell lung cancer: are third-generation drugs all the same?]
    Francesco Grossi
    Oncologia Medica A, Disease Management Team, Lung Cancer, Istituto Nazionale per la Ricerca sul Cancro, Genova
    Tumori 94:5-14. 2008
  34. ncbi [The role of adjuvant chemotherapy in the treatment of early stage NSCLC after radical surgery]
    Filippo De Marinis
    Ospedale Forlanini, Roma
    Suppl Tumori 3:S50-1. 2004
  35. ncbi Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    Nasser Hanna
    Indiana University, 535 Barnhill Dr, Room 473, Indianapolis, IN 46202, USA
    J Clin Oncol 22:1589-97. 2004
    ..To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy...
  36. ncbi Neoadjuvant strategies for non-small cell lung cancer
    Filippo De Marinis
    5th Pulmonary Oncological Unit, Carlo Forlanini Hospital, Rome
    Suppl Tumori 3:S49-51. 2004
  37. ncbi Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Via Circumvallazione 68, 83100 Avellino, Italy
    J Clin Oncol 23:3125-37. 2005
    ..Best supportive care remains important, in addition to chemotherapy or as the exclusive option for patients who are unsuitable for more aggressive treatment...
  38. ncbi Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s
    Paolo Maione
    S Giuseppe Moscati Hospital, Avellino, Italy
    J Clin Oncol 23:6865-72. 2005
    ..Using these scores in clinical practice might improve prognostic prediction for treatment planning...
  39. ncbi Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer
    Federico Cappuzzo
    Division of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139 Bologna, Italy
    Lung Cancer 42:355-61. 2003
    ....
  40. ncbi Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer
    Rafael Rosell
    Department of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Oncogene 22:3548-53. 2003
    ..The predictive value of beta-tubulin III, stathmin and RRM1 should be tested in prospective customized chemotherapy trials, the results of which will help tailor chemotherapy to improve patient survival...
  41. ncbi Supportive care in patients with advanced non-small-cell lung cancer
    M Di Maio
    National Cancer Institute Clinical Trials Unit, Naples
    Br J Cancer 89:1013-21. 2003
    ..Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults...
  42. ncbi Targeted therapy in combination with gemcitabine in non-small cell lung cancer
    Rafael Rosell
    Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Semin Oncol 30:19-25. 2003
    ..Preliminary findings that a subset of gemcitabine/cisplatin-treated patients with low ERCC1 and RRM1 mRNA levels show a significantly longer survival and highlight the possibilities of individually tailored chemotherapy...
  43. ncbi Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study
    Federico Cappuzzo
    Division of Medical Oncology, Bellaria Hospital, Bologna, Italy
    Cancer 98:128-34. 2003
    ..The objective of this trial was to evaluate the activity and safety of one of the newer platinum-based doublets as a neoadjuvant regimen in patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma (NSCLC)...
  44. ncbi Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Crit Rev Oncol Hematol 63:53-64. 2007
    ..A special focus is dedicated to neutropenia and the use of CSFs in the treatment of the three "big killers" among the solid tumours: breast cancer, lung cancer and colorectal cancer...
  45. ncbi Long-term results of induction chemotherapy followed by concurrent chemotherapy and thoracic irradiation in limited small cell lung cancer
    Ernesto Maranzano
    Radiation Oncology Center, Policlinico Hospital, Via S Sonnino, No 47, Loc S ta Lucia, 06125, Perugia, Italy
    Lung Cancer 37:79-85. 2002
    ....
  46. ncbi The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, Avellino, Italy
    Oncologist 12:1183-93. 2007
    ....